Novacyt S.A. logo

Novacyt S.A. (NCYT)

Market Closed
20 Jul, 11:03
LSE LSE
40. 30
GBX
+0.3
+0.74%
GBX
44.03M Market Cap
- P/E Ratio
- Div Yield
17,388 Volume
0 Eps
40 GBX
Previous Close
Add Transaction
Day Range
38.6 40.6
Year Range
26.6 86
Want to track NCYT and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

NCYT closed Monday higher at 40.3 GBX, an increase of 0.74% from Friday's close, completing a monthly increase of 15.1314% or 5.3 GBX. Over the past 12 months, NCYT stock gained 12.2451%.
NCYT is not paying dividends to its shareholders.
The last earnings report, released on Dec 03, 2025, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on 8 different exchanges and in various currencies, with the primary listing on XPAR (EUR).

NCYT Chart

People also search for

Eden Research PLC
2.95 GBX
0%
OBI
Ondine Biomedical Inc.
13.75 GBX
+1.8519%
OBD
Oxford Biodynamics Plc
0.13 GBX
0%
IXI
Ixico plc
8.5 GBX
0%
FAB
Fusion Antibodies Ltd.
10.75 GBX
0%

Novacyt S.A. (NCYT) FAQ

What is the stock price today?

The current price is 40.30 GBX.

On which exchange is it traded?

Novacyt S.A. is listed on LSE.

What is its stock symbol?

The ticker symbol is NCYT.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, the market cap is 44.03M.

Has Novacyt S.A. ever had a stock split?

No, there has never been a stock split.

Novacyt S.A. Profile

Biotechnology Industry
Healthcare Sector
Lyn Dafydd Rees CEO
LSE Exchange
FR0010397232 ISIN
FR Country
234 Employees
- Last Dividend
- Last Split
- IPO Date

Overview

Novacyt S.A. is a distinguished entity in the global health sector, primarily specializing in the provision of in vitro and molecular diagnostic tests. Since its inception in 2006, the company has been pivotal in addressing a range of infectious diseases. With its headquarters located in Vélizy-Villacoublay, France, Novacyt has broadened its reach, catering to diverse markets including the United Kingdom, other parts of Europe, the United States, Asia Pacific, the Middle East, and Africa. The company’s operation is structured across three main segments: Primer Design, Lab21 Products, and IT-IS International. Each of these segments plays a unique role in Novacyt’s commitment to advancing medical diagnostics, contributing to its reputation as a leader in infectious disease testing.

Products and Services

  • Primer Design

    This segment of Novacyt S.A. is dedicated to the design, manufacture, and marketing of molecular real-time qPCR testing devices and reagents. Primarily focusing on infectious diseases, products from this division are pivotal in the rapid and accurate detection of pathogens, thereby enabling timely and effective clinical interventions.

  • Lab21 Products

    Under the Lab21 Products segment, Novacyt expands its diagnostic reach to protein-based infectious disease in-vitro diagnostic device (IVD) products. This line of products is developed, manufactured, and distributed by the company, showcasing its versatility in the production of diagnostic solutions by utilizing different technological bases and methodologies for disease detection.

  • IT-IS International

    The IT-IS International segment stands out for its specialized focus on the development and manufacturing of PCR (Polymerase Chain Reaction) devices. These devices find their application not only in the life sciences arena but also in the food testing industry, illustrating the broad applicability of Novacyt's technological innovations beyond traditional medical diagnostics.

Contact Information

Address: 13 Avenue Morane Saulnier
Phone: 33 1 39 46 51 04